Corient Private Wealth LP purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 12,015 shares of the company’s stock, valued at approximately $1,257,000.
Several other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its holdings in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after acquiring an additional 319 shares during the last quarter. US Bancorp DE grew its holdings in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares during the period. Parallel Advisors LLC acquired a new stake in shares of Celcuity during the 1st quarter worth approximately $38,000. Finally, Meeder Asset Management Inc. bought a new stake in shares of Celcuity in the 4th quarter worth approximately $42,000. 63.33% of the stock is currently owned by institutional investors.
Celcuity Stock Performance
Shares of CELC opened at $95.70 on Friday. The firm’s 50 day moving average is $94.58 and its 200-day moving average is $106.76. The stock has a market capitalization of $4.68 billion, a P/E ratio of -22.26 and a beta of 0.19. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. Celcuity, Inc. has a 12-month low of $44.42 and a 12-month high of $151.02.
Analyst Ratings Changes
CELC has been the subject of several analyst reports. Wells Fargo & Company reduced their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a research report on Thursday, May 28th. Citigroup restated a “market outperform” rating on shares of Celcuity in a research report on Monday, August 17th. Stifel Nicolaus dropped their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, Guggenheim lifted their price target on Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a report on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $154.55.
Check Out Our Latest Stock Analysis on CELC
Celcuity Profile
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Further Reading
- Five stocks we like better than Celcuity
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC – Free Report).
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
